AUA 2025 Tokai Urologic Oncology Research Study (TOURS) database study, tyrosine kinase inhibitors (TKIs), immunotherapy (IO), advanced renal cell carcinoma (RCC).

PSMA and Beyond 2025 CA-IX in renal cell cancer (RCC), ZIRCON, kidney cancer, stage migration for RCC, REDECT trial, renal mass biopsy, girentuximab.

Neeraj Agarwal speaks with Praful Ravi about an individual patient data meta-analysis examining docetaxel addition to ADT plus radiation therapy in high-risk localized prostate cancer. The ISECaP ...

Risk factors for low-risk prostate cancer: A retrospective cohort study within the FinRSPC trial. July 18, 2025 Unplanned hospitalization among advanced prostate cancer patients by diabetes status-a ...

Survival benefits of Cytoreductive Nephrectomy in patients with metastatic renal cell carcinoma: evidence from a SEER-based retrospective cohort study. July 17, 2025 Genetic Insights Into ...

PSMA and Beyond PSMA-targeted prostate biopsy, MRI-guided biopsy, PIRADS 2 lesion, 68Ga-PSMA-11, PSMA guided fusion biopsy, PIRADS delineation, SUVmax and PRIMARY score.

ASCO 2025, prostate cancer, Metastatic Castration-Resistant Prostate Cancer (mCRPC), XALute Study, Xaluritamig, Cabazitaxel, Xaluritamig versus Cabazitaxel or Second Androgen Receptor-Directed Therapy ...

(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL between May 30 th and June 3 rd, 2025, was host to a prostate, testicular, and penile cancers ...

WCET 2024 optimizing stone treatment, Michelle Jo Semins, laser modalities, world’s first ureteroscopy and laser lithotripsy, MOSES technology.

AUA 2025 thermal safety of high-powered lasers during endoscopic stone surgery, renal calyceal, parenchymal temperatures, laser lithotripsy, 60W Super-Pulse Thulium Fiber Laser (TFL), 120W ...

Zachary Klaassen speaks with Adrien Holzgreve about the FLEX-MRT trial, which aims to personalize lutetium-177 PSMA radioligand therapy delivery. Currently, Pluvicto™ follows fixed dosing from the ...

ASCO 2025, bladder cancer, muscle-invasive bladder cancer (MIBC), SURE-01 trial, radical cystectomy, neoadjuvant sacituzumab govitecan (SG), monotherapy, sacituzumab govitecan followed by radical ...